Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Multiple Myeloma 26Prostatic Neoplasms 24Breast Neoplasms 23Leukemia, Myeloid, Acute 20Carcinoma, Non-Small-Cell Lung 20Lymphoma 19Melanoma 16Lymphoma, Non-Hodgkin 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Ovarian Neoplasms 13Colorectal Neoplasms 12Wilms Tumor 11Myelodysplastic Syndromes 10Hodgkin Disease 10Squamous Cell Carcinoma of Head and Neck 9Sarcoma 9Neoplasm Metastasis 9Lung Neoplasms 9Fallopian Tube Neoplasms 9Carcinoma, Renal Cell 9Burkitt Lymphoma 9Rhabdomyosarcoma 8Rhabdoid Tumor 8Neoplasms 8Leukemia 8Hepatoblastoma 8Glioma 8Sarcoma, Ewing 7Osteosarcoma 7Neuroectodermal Tumors, Primitive, Peripheral 7

Interventions

durvalumab 1Radiotherapy, Intensity-Modulated 1Immunoglobulin G 1Disulfides 1Cetuximab 1(225)Ac-DOTA-c(RGDyK) 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Carcinoma × 30 days × Clear all
NCT03258554 2026-06-02

Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin

National Cancer Institute (NCI)

Phase 2/3 Completed
196 enrolled 31 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡